2022
Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study
Cox H, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A, Mohr-Holland E, Daniels J, Cudahy PGT, Nicol MP, Borrell S, Reinhard M, Doetsch A, Beisel C, Gagneux S, Warren RM, Furin J. Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study. Journal Of Clinical Microbiology 2022, 60: e02362-21. PMID: 35170980, PMCID: PMC8925891, DOI: 10.1128/jcm.02362-21.Peer-Reviewed Original ResearchConceptsDrug susceptibility testingRifampicin-resistant tuberculosisShort regimenMDR/RR-TB patientsMDR/RR-TBRR-TB patientsRetrospective cohort studyMore effective treatment regimensHigh-burden settingsRoutine drug susceptibility testingTB drug resistanceEffective treatment regimensWhole-genome sequencingTolerable regimensCohort studyRetrospective cohortRR-TBRegimen changeTreatment regimensTreatment recommendationsPatient outcomesTreatment individualizationClinical dataIndividualized treatmentIneffective drugs
2021
Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study
Cox H, Salaam-Dreyer Z, Goig GA, Nicol MP, Menardo F, Dippenaar A, Mohr-Holland E, Daniels J, Cudahy PGT, Borrell S, Reinhard M, Doetsch A, Beisel C, Reuter A, Furin J, Gagneux S, Warren RM. Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study. The Lancet Microbe 2021, 2: e584-e593. PMID: 34766068, PMCID: PMC8563432, DOI: 10.1016/s2666-5247(21)00144-0.Peer-Reviewed Original ResearchConceptsFirst-line tuberculosis treatmentPrevious tuberculosis treatmentRifampicin-resistant tuberculosisRifampicin-monoresistant tuberculosisTuberculosis treatmentHIV positivityCohort studyLarge-scale prospective cohort studyResistance acquisitionPrevious treatmentRetrospective cohort studyProspective cohort studyTuberculosis drug resistancePatient-level dataLogistic regression analysisWhole-genome sequencingMolecular epidemiology studiesProspective databaseMDR tuberculosisRetrospective cohortFemale sexHigh burdenPatientsHIVEpidemiology studies
2020
Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study
Cudahy PGT, Wilson D, Cohen T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases 2020, 20: 789. PMID: 33097000, PMCID: PMC7585300, DOI: 10.1186/s12879-020-05515-4.Peer-Reviewed Original ResearchConceptsM. tuberculosis infectionRecurrent tuberculosisSuccessful treatmentTuberculosis recurrenceHazard ratioSmear gradeTuberculosis infectionRisk factorsSmear-positive pulmonary tuberculosisCox proportional hazards modelSputum smear gradeRepetitive unit-variable number tandem repeat (MIRU-VNTR) typingHigh-burden settingsRisk of recurrenceProportional hazards modelSuccessful treatment completionRecurrent diseaseCohort studyPulmonary tuberculosisBurden settingsClinical presentationRecurrent episodesInitial episodeNumber tandem repeat typingTreatment completion